Response to correspondence concerning: "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients".
作者信息
Lammers A J J, Brohet R M, Theunissen R E P, Koster C, Rood R, Verhagen D W M, Brinkman K, Hassing R J, Dofferhoff A, El Moussaoui R, Hermanides G, Ellerbroek J, Bokhizzou N, Visser H, van den Berge M, Bax H, Postma D F, Groeneveld P H P
机构信息
Isala, Zwolle, The Netherlands.
Department of Epidemiology and Statistics, Isala Academy, Zwolle, The Netherlands.
出版信息
Int J Infect Dis. 2021 Feb;103:478-479. doi: 10.1016/j.ijid.2020.12.008. Epub 2020 Dec 9.
Abstract
摘要
相似文献
1
Response to correspondence concerning: "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients".对关于“早期使用羟氯喹而非氯喹可降低COVID-19患者入住重症监护病房的几率”的信件的回复
Int J Infect Dis. 2021 Feb;103:478-479. doi: 10.1016/j.ijid.2020.12.008. Epub 2020 Dec 9.
2
Response to "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients".对“早期使用羟氯喹而非氯喹可降低COVID-19患者入住重症监护病房的几率”的回应。
Int J Infect Dis. 2021 Feb;103:560-561. doi: 10.1016/j.ijid.2020.12.006. Epub 2020 Dec 9.
3
Comparison of hospital treatment strategy or of treatment actually received in COVID-19?: Commenting on: Lammers AJJ, Brohet RM, Theunissen REP, Koster C, Rood R, Verhagen DWM, et al. Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. Int J Infect Dis. 2020 September.2019冠状病毒病（COVID-19）医院治疗策略或实际接受治疗情况的比较：对以下文献的评论：Lammers AJJ、Brohet RM、Theunissen REP、Koster C、Rood R、Verhagen DWM等。早期使用羟氯喹而非氯喹可降低COVID-19患者入住重症监护病房的几率。《国际传染病杂志》。2020年9月。
Int J Infect Dis. 2021 Feb;103:516. doi: 10.1016/j.ijid.2020.12.007. Epub 2020 Dec 9.
4
Chloroquine and hydroxychloroquine to treat COVID-19: between hope and caution.氯喹和羟氯喹治疗新型冠状病毒肺炎：希望与谨慎并存
Clin Toxicol (Phila). 2021 Jan;59(1):70-71. doi: 10.1080/15563650.2020.1748194. Epub 2020 Apr 2.
5
Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine.抗2019冠状病毒病（COVID-19）的氨基喹啉：氯喹或羟氯喹。
Int J Antimicrob Agents. 2020 Apr;55(4):105945. doi: 10.1016/j.ijantimicag.2020.105945. Epub 2020 Mar 17.
6
Ototoxicity prevention during the SARS-CoV-2 (COVID-19) emergency.在 SARS-CoV-2（COVID-19）紧急情况下预防耳毒性。
J Glob Antimicrob Resist. 2020 Dec;23:263-264. doi: 10.1016/j.jgar.2020.09.030. Epub 2020 Oct 17.
7
Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story.氯喹和羟氯喹治疗 COVID-19：一个永无止境的故事。
Appl Microbiol Biotechnol. 2021 Feb;105(4):1333-1343. doi: 10.1007/s00253-021-11094-4. Epub 2021 Jan 30.
8
Chloroquine and Hydroxychloroquine in COVID-19: Practice Implications for Healthcare Professionals.氯喹和羟氯喹在2019冠状病毒病中的应用：对医疗保健专业人员的实践启示
J Coll Physicians Surg Pak. 2020 Oct;30(10):124-128. doi: 10.29271/jcpsp.2020.supp2.124.
9
10
Use of chloroquine or hydroxychloroquine in treatment of COVID-19: is it ethical?使用氯喹或羟氯喹治疗新型冠状病毒肺炎：这是否符合伦理？
Cent Eur J Public Health. 2020 Sep;28(3):246-247. doi: 10.21101/cejph.a6464.
引用本文的文献
1
Azithromycin through the Lens of the COVID-19 Treatment.从新冠肺炎治疗视角看阿奇霉素
Antibiotics (Basel). 2022 Aug 5;11(8):1063. doi: 10.3390/antibiotics11081063.
Zotero 插件